A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types (NCT07503808)
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.
Who can join: Review the eligibility criteria below.
Location: Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Florida Cancer Specialists — Sarasota, Florida
- Karmanos Cancer Institute — Detroit, Michigan
- START New York Long Island, LLC — Lake Success, New York
- SCRI Oncology Partners — Nashville, Tennessee
- NEXT Texas LLC - Austin — Austin, Texas
- START Dallas Fort Worth, LLC — Fort Worth, Texas
- MD Anderson — Houston, Texas
- NEXT Texas LLC - Houston — Houston, Texas
- NEXT Texas LLC - Dallas — Irving, Texas
- NEXT Texas LLC - San Antonio — San Antonio, Texas
- START San Antonio, LLC — San Antonio, Texas
- START Mountain Region, LLC — West Valley City, Utah
- NEXT Texas LLC - Virginia — Fairfax, Virginia
- Medical Oncology Associates — Spokane, Washington
📞 Contact the Study Coordinator
Phone: (855) 433-2246
Email: IDEAYAClinicalTrials@ideayabio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Esophageal Squamous Cell Carcinoma
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy — Fort Myers, Florida
- Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC — Atlanta, Georgia
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) — Pittsburgh, Pennsylvania
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) — Tucson, Arizona
- Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer — Montreal, Quebec
Explore by condition: All Esophageal Squamous Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.